New Clinical Trial Reduces Breast Cancer Risk by 35%
A recent study has shown promising results for a new treatment approach for advanced triple-negative breast cancer. The combination of Trodelvy, an antibody-drug conjugate, and Merck’s immunotherapy Keytruda has been found to significantly reduce the risk of cancer progression by 35%. This finding was presented during a large trial at the American Society of Clinical … Read more